MA49069A - Procédés et compositions pour le traitement d'apnée du sommeil - Google Patents

Procédés et compositions pour le traitement d'apnée du sommeil

Info

Publication number: MA49069A
Authority: MA; Morocco
Prior art keywords: compositions; treatment; methods; sleep apnea; apnea
Prior art date: 2017-04-28

Application number

MA049069A

Other languages

English (en)

Inventor

Luigi Taranto-Montemurro

D Andrew Wellman

Original Assignee

Brigham & Womens Hospital Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-04-28

Filing date

2018-04-26

Publication date

2020-03-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63918622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA49069(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-04-26 Application filed by Brigham & Womens Hospital Inc filed Critical Brigham & Womens Hospital Inc

2020-03-04 Publication of MA49069A publication Critical patent/MA49069A/fr

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pulmonology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

MA049069A 2017-04-28 2018-04-26 Procédés et compositions pour le traitement d'apnée du sommeil MA49069A (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201762491504P	2017-04-28	2017-04-28
US201762558814P	2017-09-14	2017-09-14
PCT/US2018/029518 WO2018200775A1 (fr)	2017-04-28	2018-04-26	Procédés et compositions pour le traitement d'apnée du sommeil

Publications (1)

Publication Number	Publication Date
MA49069A true MA49069A (fr)	2020-03-04

Family

ID=63918622

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA049069A MA49069A (fr)	2017-04-28	2018-04-26	Procédés et compositions pour le traitement d'apnée du sommeil

Country Status (21)

Country	Link
US (5)	US11123313B2 (fr)
EP (1)	EP3615016A4 (fr)
JP (3)	JP7373997B2 (fr)
KR (3)	KR20250145704A (fr)
CN (2)	CN119185558A (fr)
AU (3)	AU2018260666B2 (fr)
CA (1)	CA3061468A1 (fr)
CO (1)	CO2019013180A2 (fr)
CR (1)	CR20190546A (fr)
DO (1)	DOP2019000274A (fr)
EC (1)	ECSP19084058A (fr)
GE (6)	GEAP202416602A (fr)
MA (1)	MA49069A (fr)
MX (2)	MX394941B (fr)
MY (1)	MY200172A (fr)
NI (1)	NI201900110A (fr)
PH (1)	PH12019502427A1 (fr)
SG (2)	SG11201909973UA (fr)
UA (1)	UA127759C2 (fr)
WO (1)	WO2018200775A1 (fr)
ZA (1)	ZA201907158B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN119185558A (zh) *	2017-04-28	2024-12-27	布里格姆妇女医院	用于治疗睡眠呼吸暂停的方法和组合物
CN111670050A (zh)	2018-01-30	2020-09-15	爱普宁公司(特拉华)	用于治疗睡眠呼吸暂停的方法和组合物
CN108309261B (zh) *	2018-02-11	2020-05-22	西安交通大学	一种猝死预警方法及装置和系统
WO2019245975A1 (fr)	2018-06-17	2019-12-26	Axsome Therapeutics, Inc.	Compositions pour l'administration de réboxétine
US20200147093A1 (en)	2018-10-15	2020-05-14	Axsome Therapeutics, Inc.	Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en)	2018-10-15	2021-06-01	Axsome Therapeutics, Inc.	Use of reboxetine to treat narcolepsy
CA3117766A1 (fr) *	2018-10-31	2020-05-07	Apnimed, Inc. (Delaware)	Methodes et compositions pour le traitement de l'apnee du sommeil
ES3049086T3 (en) *	2019-02-08	2025-12-12	Brigham & Womens Hospital Inc	Methods and compositions for treating sleep apnea
US20220362221A1 (en) *	2019-11-04	2022-11-17	Apnimed, Inc. (Delaware)	Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
US12616702B2 (en)	2019-12-03	2026-05-05	Axsome Therapeutics, Inc.	Use of reboxetine to treat narcolepsy
EP4146621A1 (fr)	2020-05-05	2023-03-15	Apnimed, Inc. (Delaware)	Formes polymorphes de chlorhydrate de (r)-oxybutynine
CN114159568B (zh) *	2020-09-11	2025-08-01	北京原基华毅生物科技有限公司	Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
RU2757470C1 (ru) *	2020-11-19	2021-10-18	Ренат Рашитович Ахмеров	Способ лечения храпа с помощью введения тромбоцитарной аутологичной плазмы
US20240075035A1 (en) *	2021-01-14	2024-03-07	Apnimed, Inc. (Delaware)	Methods and compositions for treating sleep apnea
CA3210092A1 (fr) *	2021-03-04	2022-09-09	Lawrence G. Miller	Combinaison de reboxetine et d'un antagoniste du recepteur muscarinique (arm) destinee a etre utilisee dans le traitement de l'apnee du sommeil
CN117177741A (zh) *	2021-04-16	2023-12-05	爱普宁公司(特拉华)	用于治疗睡眠呼吸暂停的去甲肾上腺素再摄取抑制剂和大麻素的组合
JP2024523876A (ja) *	2021-06-17	2024-07-02	アプニメッド，インコーポレイテッド（デラウェア）	睡眠時無呼吸を治療するためのノルエピネフリン再取り込み阻害剤
JP2024534173A (ja) *	2021-08-31	2024-09-18	アプニメッド，インコーポレイテッド（デラウェア）	睡眠時無呼吸を治療するための方法及び組成物
CA3259602A1 (fr)	2021-12-22	2023-06-29	Bayer Aktiengesellschaft	Combinaison d’un antagoniste alpha 2-adrénocepteur de sous-type c (alpha-2 c) et d’un antagoniste du récepteur muscarinique pour le traitement de l’apnée du sommeil
MX2024007768A (es)	2021-12-22	2024-07-01	Bayer Ag	Combinacion de un antagonista de adrenoreceptor a2 subtipo c (alfa-2c) con un inhibidor de recaptacion de norepinefrina para el tratamiento de apnea del sue?o.
IL313648A (en) *	2021-12-22	2024-08-01	Bayer Ag	Combination of a TASK1/3 channel blocker with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
EP4522149A1 (fr) *	2022-05-13	2025-03-19	Apnimed, Inc. (Delaware)	Méthodes et compositions pour le traitement de l'apnée du sommeil
US20260041659A1 (en) *	2024-08-07	2026-02-12	Yogesh Dandiker	Topical atomoxetine and oxybutynin for obstructive sleep apnea
US12565478B1 (en)	2025-01-21	2026-03-03	Axsome Therapeutics, Inc.	(S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU767877B2 (en)	1999-05-20	2003-11-27	Sepracor, Inc.	Methods for treatment of asthma using S-oxybutynin
WO2001062236A2 (fr) *	2000-02-24	2001-08-30	Pharmacia & Upjohn Company	Nouvelles combinaisons medicamenteuses
WO2006023703A2 (fr)	2004-08-20	2006-03-02	Cypress Bioscience, Inc.	Methode de traitement de troubles respiratoires lies au sommeil
JP2008524332A (ja) *	2004-12-20	2008-07-10	コレジウムファーマシューティカル，インク．	睡眠傷害のための医薬組成物
CN107007602A (zh) *	2011-01-28	2017-08-04	辉达斯医学研究所	治疗阻塞性睡眠呼吸暂停的方法
CN119185558A (zh) *	2017-04-28	2024-12-27	布里格姆妇女医院	用于治疗睡眠呼吸暂停的方法和组合物
CN111670050A (zh)	2018-01-30	2020-09-15	爱普宁公司(特拉华)	用于治疗睡眠呼吸暂停的方法和组合物

2018
- 2018-04-26 CN CN202411366994.9A patent/CN119185558A/zh active Pending
- 2018-04-26 MA MA049069A patent/MA49069A/fr unknown
- 2018-04-26 GE GEAP202416602A patent/GEAP202416602A/en unknown
- 2018-04-26 US US16/609,048 patent/US11123313B2/en active Active
- 2018-04-26 GE GEAP201816320A patent/GEP20257788B/en unknown
- 2018-04-26 UA UAA201910615A patent/UA127759C2/uk unknown
- 2018-04-26 AU AU2018260666A patent/AU2018260666B2/en active Active
- 2018-04-26 CR CR20190546A patent/CR20190546A/es unknown
- 2018-04-26 KR KR1020257032249A patent/KR20250145704A/ko active Pending
- 2018-04-26 MX MX2019012729A patent/MX394941B/es unknown
- 2018-04-26 JP JP2019558554A patent/JP7373997B2/ja active Active
- 2018-04-26 KR KR1020197034523A patent/KR102682159B1/ko active Active
- 2018-04-26 GE GEAP202316320A patent/GEAP202316320A/en unknown
- 2018-04-26 SG SG11201909973U patent/SG11201909973UA/en unknown
- 2018-04-26 CA CA3061468A patent/CA3061468A1/fr active Pending
- 2018-04-26 SG SG10202111623TA patent/SG10202111623TA/en unknown
- 2018-04-26 GE GEAP202115226A patent/GEAP202115226A/en unknown
- 2018-04-26 WO PCT/US2018/029518 patent/WO2018200775A1/fr not_active Ceased
- 2018-04-26 MY MYPI2019006319A patent/MY200172A/en unknown
- 2018-04-26 GE GEAP201815757A patent/GEP20247617B/en unknown
- 2018-04-26 CN CN201880042623.1A patent/CN110799181A/zh active Pending
- 2018-04-26 GE GEAP201815226A patent/GEP20227387B/en unknown
- 2018-04-26 KR KR1020247009759A patent/KR20240042261A/ko not_active Ceased
- 2018-04-26 EP EP18791670.5A patent/EP3615016A4/fr active Pending
2019
- 2019-10-24 MX MX2022010349A patent/MX2022010349A/es unknown
- 2019-10-25 DO DO2019000274A patent/DOP2019000274A/es unknown
- 2019-10-25 NI NI201900110A patent/NI201900110A/es unknown
- 2019-10-25 PH PH12019502427A patent/PH12019502427A1/en unknown
- 2019-10-29 ZA ZA2019/07158A patent/ZA201907158B/en unknown
- 2019-11-25 EC ECSENADI201984058A patent/ECSP19084058A/es unknown
- 2019-11-26 CO CONC2019/0013180A patent/CO2019013180A2/es unknown
2021
- 2021-09-10 US US17/471,892 patent/US20210401777A1/en not_active Abandoned
2022
- 2022-09-27 AU AU2022241471A patent/AU2022241471A1/en not_active Abandoned
2023
- 2023-06-30 JP JP2023108387A patent/JP2023139000A/ja active Pending
- 2023-07-19 US US18/355,178 patent/US20240189261A1/en not_active Abandoned
2024
- 2024-03-04 US US18/594,885 patent/US20240261239A1/en not_active Abandoned
2025
- 2025-07-10 US US19/265,336 patent/US20260007618A1/en active Pending
- 2025-07-31 JP JP2025128090A patent/JP2025169279A/ja active Pending
- 2025-09-11 AU AU2025230729A patent/AU2025230729A1/en active Pending

Also Published As

Publication number	Publication date
PH12019502427A1 (en)	2020-10-05
WO2018200775A1 (fr)	2018-11-01
DOP2019000274A (es)	2019-12-30
GEAP202416602A (en)	2024-10-10
BR112019022483A2 (pt)	2020-05-12
MX2022010349A (es)	2022-09-19
MX394941B (es)	2025-03-24
AU2018260666A1 (en)	2019-11-14
MY200172A (en)	2023-12-12
US11123313B2 (en)	2021-09-21
CR20190546A (es)	2020-04-08
ECSP19084058A (es)	2020-01-31
US20240189261A1 (en)	2024-06-13
NZ758564A (en)	2023-12-22
EP3615016A1 (fr)	2020-03-04
GEP20227387B (en)	2022-06-10
SG10202111623TA (en)	2021-12-30
CN119185558A (zh)	2024-12-27
AU2018260666B2 (en)	2022-07-21
KR20250145704A (ko)	2025-10-13
US20240261239A1 (en)	2024-08-08
US20210401777A1 (en)	2021-12-30
UA127759C2 (uk)	2023-12-27
US20260007618A1 (en)	2026-01-08
CN110799181A (zh)	2020-02-14
US20200054583A1 (en)	2020-02-20
GEP20257788B (en)	2025-08-25
AU2025230729A1 (en)	2025-10-02
JP2023139000A (ja)	2023-10-03
CA3061468A1 (fr)	2018-11-01
SG11201909973UA (en)	2019-11-28
GEP20247617B (en)	2024-04-25
JP2025169279A (ja)	2025-11-12
NI201900110A (es)	2020-03-18
KR20240042261A (ko)	2024-04-01
MX2019012729A (es)	2019-12-19
GEAP202316320A (en)	2023-09-11
ZA201907158B (en)	2021-09-29
KR102682159B1 (ko)	2024-07-08
EP3615016A4 (fr)	2021-02-24
GEAP202115226A (en)	2021-12-27
KR20190140019A (ko)	2019-12-18
JP7373997B2 (ja)	2023-11-06
AU2022241471A1 (en)	2022-10-27
CO2019013180A2 (es)	2020-02-07
JP2020517719A (ja)	2020-06-18

Publication	Publication Date	Title
EP3615016A4 (fr)	2021-02-24	Procédés et compositions pour le traitement d'apnée du sommeil
EP3612215A4 (fr)	2021-05-26	Compositions et procédés pour le traitement d'inflammation pulmonaire
EP3630072A4 (fr)	2021-03-10	Procédés et compositions pour le traitement d'une somnolence excessive
MA50849A (fr)	2020-09-02	Substances et procédés pour le traitement d'hémoglobinopathies
MA71705A (fr)	2025-05-30	Substances et procédés pour le traitement d'hémoglobinopathies
EP3947715A4 (fr)	2022-11-23	Procédés et compositions pour le traitement du cancer
EP3894392A4 (fr)	2022-08-24	Compositions et procédés pour le traitement du cancer
MA52861A (fr)	2021-05-05	Méthodes et compositions pour le traitement de l'apnée du sommeil
MA51306A (fr)	2020-10-28	Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
EP3645739A4 (fr)	2021-07-14	Procédés et compositions pour le traitement du mélanome
MA45798A (fr)	2019-06-05	Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
EP3905976A4 (fr)	2022-09-21	Systèmes et procédés pour le traitement de l'apnée obstructive du sommeil
EP3555077A4 (fr)	2021-01-06	Compositions et procédés pour le traitement du cancer
EP3641829A4 (fr)	2021-04-21	Promédicament d'interféron pour le traitement du cancer
MA42819A (fr)	2018-07-25	Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae
EP3448421A4 (fr)	2019-12-25	Procédés et compositions pour la prévention et le traitement d'adhérences chirurgicales
EP3341391A4 (fr)	2019-03-06	Compositions et procédés pour le traitement de la douleur
MA53873A (fr)	2022-01-19	Compositions et procédés pour le traitement de la presbytie
EP3390642A4 (fr)	2019-06-26	Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
MA51056A (fr)	2020-10-14	Compositions et méthodes pour le traitement d'affections métaboliques
MA43170A (fr)	2018-09-12	Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer
EP3920898A4 (fr)	2022-11-09	Méthodes et compositions pour le traitement de l'apnée du sommeil
EP3833340A4 (fr)	2021-09-29	Compositions et procédés de traitement de la presbytie
EP3358929A4 (fr)	2019-06-05	Procédés et appareils pour le traitement d'une matière agricole
EP3405172A4 (fr)	2019-09-18	Procédés et compositions pour le traitement du vieillissement cutané